1.Chang, S, Sievert, DM, Hageman, JC, et al. Infection with vancomycin-resistant Staphylococcus aureus containing the vanA resistance gene. N Engl J Med 2003; 348:1342–1347.
2.Howden, BP, Ward, PB, Charles, PGP, et al. Treatment outcomes for serious infections caused by methicillin-resistant Staphylococcus aureus with reduced vancomycin susceptibility. Clin Infect Dis 2004; 38:521–528.
3.Carpenter, CF, Chambers, HF. Daptomycin: another novel agent for treating infections due to drug-resistant gram-positive pathogens. Clin Infect Dis 2004; 38:994–1000.
4.Akins, RL, Rybak, MJ. Bactericidal activities of two daptomycin regimens against clinical strains of glycopeptide intermediate-resistant Staphylococcus aureus, vancomycin-resistant Enterococcus faecium, and methicillin-resistant Staphylococcus aureus isolates in an in vitro pharmacodynamic model with simulated endocardial vegetations. Antimicrob Agents Chemother 2001; 45:454–459.
5.Cubicin (daptomycin for injection) [package insert]. Lexington, MA: Cubist Pharmaceuticals; 2003.
6.LaPlante, KL, Rybak, MJ. Impact of high-inoculum Staphylococcus aureus on the activities of nafcillin, vancomycin, linezolid, and daptomycin, alone and in combination with gentamicin, in an in vitro pharmacodynamic model. Antimicrob Agents Chemother 2004; 48:4465–4472.
7.Cha, R, Rybak, MJ. Daptomycin against multiple drug-resistant Staphylococcus and Enterococcus isolates in an in vitro pharmacodynamic model with simulated endocardial vegetations. Diagn Microbiol Infect Dis 2003; 47:539–546.
8.Steenbergen, JN, Alder, J, Thome, GM, Tally, FP. Daptomycin: a lipopeptide antibiotic for the treatment of serious gram-positive infections. J Antimicrob Chemother 2005; 55:283–288.
9.Sakoulas, G, Eliopoulos, GM, Adler, J, Thauvin-Eliopoulos, C. Efficacy of daptomycin in experimental endocarditis due to methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 2003; 47:1714–1718.
10.Rand, KH, Houck, HJ. Synergy of daptomycin with oxacillin and other B-lactams against methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 2004; 48:2871–2875.
11.Mohan, SS, Mcdermott, BP, Cunha, BA. Methicillin-resistant Staphylococcus aureus prosthetic valve endocarditis with paravalvular abscess treated with daptomycin. Heart Lung 2005; 34:69–71.
12.Silverman, JA, Oliver, N, Andrew, T, Li, T. Resistance studies with daptomycin. Antimicrob Agents Chemother 2001; 45:1799–1802.
13.Mangilli, A, Bica, I, Snydman, DR, Hamer, DH. Daptomycin-resistant, methicillin-resistant, Staphylococcus aureus bacteremia. Clin Infect Dis 2005; 40:1058–1060.
14.Wise, R, Andrews, JM, Ashby, JP. Activity of daptomycin against gram-positive pathogens: a comparison with other agents and the determination of a tentative breakpoint. J Antimicrob Chemother 2001; 48:563–567.